Unknown

Dataset Information

0

The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera.

ABSTRACT:

SUBMITTER: Wang L 

PROVIDER: S-EPMC4532371 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera.

Wang L L   Swierczek S I SI   Lanikova L L   Kim S J SJ   Hickman K K   Walker K K   Wang K K   Drummond J J   Doddapaneni H H   Reid J G JG   Muzny D M DM   Gibbs R A RA   Wheeler D A DA   Prchal J T JT  

Leukemia 20140127 4

Similar Datasets

Unknown Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera.
| S-EPMC8448748 | biostudies-literature
Unknown Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model.
| S-EPMC9015207 | biostudies-literature
Unknown JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes.
| S-EPMC8993923 | biostudies-literature
Unknown The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.
| S-EPMC1434515 | biostudies-literature
Unknown Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
| S-EPMC4979103 | biostudies-literature
Unknown Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the <i>JAK2</i><sup>V617F</sup> mutation.
| S-EPMC5566046 | biostudies-literature
Unknown JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling.
| S-EPMC7343343 | biostudies-literature
Unknown Neutrophil-to-Lymphocyte ratio as surrogate for JAK2&lt;sup&gt;V617F&lt;/sup&gt; suppression and event-free survival in polycythemia vera.
| S-EPMC12328675 | biostudies-literature
Unknown A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation.
| S-EPMC7385920 | biostudies-literature
Unknown A phase 1 study of the Janus kinase 2 (JAK2)<sup>V617F</sup> inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
| S-EPMC8207330 | biostudies-literature